* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

OSI Pharmaceuticals

                   

Cyclacel Announces Completion Of Enrollment In Phase 2 Trial Of Sapacitabine In Elderly AML

medicalnewstoday.com
19 hrs ago
        

lCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the completion of enrollment as per protocol in the Phase 2 clinical trial of sapacitabine, the Company's oral nucleoside analogue, in elderly...

add comment

OSI Pharmaceuticals to Announce Third Quarter Financial Results on October 22, 2008 (Business Wire)

yahoo.com
Oct 10, 2008 2 related
        

MELVILLE, N.Y.----OSI Pharmaceuticals, Inc. announced today that its third quarter 2008 financial results will be released on October 22, 2008, after the markets close. Following the announcement OSI's management will host a...

add comment
                   

Cash reserves may mean it's time for acquisitions for drugmakers

app.com
Oct 10, 2008
        

Pfizer Inc., GlaxoSmithKline Plc and Merck & Co., flush with cash, are prowling for new products through acquisitions as the global credit crunch makes it harder for small biotechnology companies to finance their research.

add comment

OSI, Genentech Slump on Avastin-Tarceva Miss

pharmiweb.co.uk
Oct 10, 2008
        

OSI, Genentech Slump on Avastin-Tarceva Miss. BIOWORLD Today - Oct. 10, 2008 Byline: Donna Young, Washington Editor Shares of Genentech Inc. and OSI Pharmaceuticals Inc. took a beating Monday on the news that their targeted...

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

Cyclacel Announces Completion of Enrollment in Phase 2 Trial of Sapacitabine in Elderly AML

genengnews.com
Oct 9, 2008 5 related
        

News source: Business Wire Cyclacel Pharmaceuticals, Inc. announced today the completion of enrollment as per protocol in the Phase 2 clinical trial of sapacitabine, the Company's oral nucleoside analogue, in elderly patients...

add comment
                   

Zacks Analyst Blog Highlights: The Potash Corporation of Saskatchewan, Inc., Freddie Mac, Fannie...

centredaily.com
Oct 9, 2008 4 related
        

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the...

add comment

Genentech Has Mixed Results In Cancer Fight (at Forbes.com)

yahoo.com
Oct 8, 2008 11 related
        

Genentech has been battling cancer, beating one and succumbing to another. ) announced that their drug Rituxan was able to slow the progression of lymphocytic leukemia in a late-stage trial that treated patients who had...

add comment

Genentech Has Mixed Results In Cancer Fight

forbes.com
Oct 8, 2008 3 related
        

Genentech has been battling cancer, beating one and succumbing to another. ) announced that their drug Rituxan was able to slow the progression of lymphocytic leukemia in a late-stage trial that treated patients who had...

add comment
bizjournals.com: San Francisco bizjournals.com

Genentech Set Back by Drug Study

wsj.com
Oct 6, 2008 35 related
        

Genentech Inc. and OSI Pharmaceuticals Inc. said a late-stage trial showed that adding the cancer medicine Avastin to the drug Tarceva didn't prolong the lives of patients with advanced lung cancer. The companies said, however,...

add comment
                   

Movers: Wells Fargo, Wachovia, Citigroup, ImClone, eBay

businessweek.com
Oct 6, 2008 1 related
        

Wells Fargo says appellate court has entered an order vacating New York Supreme Court Justice Charles Ramos's order of Oct. 4 that granted emergency injunctive relief extending Exclusivity Agreement between Citigroup and...

add comment
1 2 3 4 5 next »